- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05757492
Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors
February 16, 2024 updated by: Coherus Biosciences, Inc.
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CHS-006, as Monotherapy and in Combination With Toripalimab, in Participants With Advanced Solid Tumors
This phase 1 open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of CHS-006 in combination with toripalimab in 2 phases.
Phase 1 (Dose Optimization phase) will explore 2 different dose combinations in participants with advanced/metastatic solid tumors (except pancreatic) and Phase 2 (Indication-specific Expansion phase) will use one selected dose in specific tumor types (non-small cell lung cancer-non squamous [NSCLC-NS] and Hepatocellular carcinoma [HCC])
Study Overview
Status
Active, not recruiting
Intervention / Treatment
Detailed Description
The Dose Optimization phase will enroll participants with advanced/metastatic solid tumors (except pancreatic).
Up to 20 participants will be randomized into two dosing arms.
Two different primary advanced solid tumors have been selected for investigation of antitumor activity in the Indication-specific Expansion phase.
Up to 40 participants will be enrolled into each Indication-specific Expansion phase cohort.
All participants in both phases will receive CHS-006 in combination with toripalimab intravenously (IV) every 3 weeks (Q3W).
Study Type
Interventional
Enrollment (Actual)
22
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Nevada
-
Reno, Nevada, United States, 89502
- Renown Institute for Cancer
-
-
Ohio
-
Canton, Ohio, United States, 44718
- Gabrail Cancer and Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Males and females, ≥18 years old;
- Histopathologically or cytologically confirmed advanced solid tumor (except pancreatic) with disease progression after at least 1 prior line of standard therapy (Dose Optimization phase);
- Tumor-specific criteria (Indication-specific Expansion phase):
- NSCLC-NS (without sensitizing EGFR/ALK/ROS-1/MET mutations) 2nd line plus (2L+): has received and progressed on at least 1 prior chemotherapy regimen. Prior treatment with both anti-PD-1 therapy and platinum-based chemotherapy either concurrently or sequentially are eligible.
- Hepatocellular carcinoma (HCC) 2L+: has received and progressed on at least 1 prior anticancer regimen. Participants with prior treatment with an anti-PD-1 or PD-L1 agent are eligible.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and expected survival ≥12 weeks;
- At least 1 measurable lesion per RECIST v1.1;
- Adequate organ and marrow function
Exclusion Criteria:
- Current or prior use of systemic anticancer therapy, including but not limited to chemotherapy, immunotherapy, biologic therapy, hormone therapy, and targeted therapy, within 28 days prior to the 1st dose of CHS-006;
- NSCLC participants with genomic mutations (e.g., EGFR, ALK, ROS-1, MET, etc.) for which FDA-approved targeted therapies are available or require progression on appropriate prior to enrollment;
- Prior exposure to monoclonal antibodies (mAbs) targeting TIGIT or any of its ligands, including CD155, CD112, or CD113;
- Major surgery within 28 days prior to the 1st dose of CHS-006 or still recovering from prior surgery;
- Symptomatic or untreated central nervous system (CNS) metastases;
- Use of therapeutic immunosuppressive medication within 28 days prior to the 1st planned dose of CHS-006;
- Receipt of live, attenuated vaccination within 30 days prior to the 1st dose of CHS- 006;
- History of active autoimmune disease within the past 2 years, with the following exceptions: vitiligo, alopecia, endocrinopathies controlled by hormone replacement therapy, rheumatoid arthritis and other arthropathies that have not required immunosuppression other than nonsteroidal anti-inflammatory agents, celiac disease controlled by diet, or psoriasis controlled with topical medication;
- Participants with another active solid tumor that has not been curatively treated.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Dose Optimization Phase - Arm A
Advanced solid tumor participants will receive CHS-006 in combination with toripalimab Q3W
|
Arm A participants will receive CHS-006 administered via IV Q3W.
Other Names:
Arm B participants will receive toripalimab administered via IV Q3W.
Other Names:
|
Active Comparator: Dose Optimization Phase - Arm B
Advanced solid tumor participants will receive CHS-006 in combination with toripalimab Q3W
|
Arm A participants will receive CHS-006 administered via IV Q3W.
Other Names:
Arm B participants will receive toripalimab administered via IV Q3W.
Other Names:
|
Active Comparator: Indication-specific Expansion Phase - Cohort 1 NSCLC-NS
NSCLC-NS participants will receive CHS-006 in combination with toripalimab Q3W
|
Arm A participants will receive CHS-006 administered via IV Q3W.
Other Names:
Arm B participants will receive toripalimab administered via IV Q3W.
Other Names:
|
Active Comparator: Indication-specific Expansion Phase - Cohort 2 HCC
HCC participants will receive CHS-006 in combination with toripalimab Q3W
|
Arm A participants will receive CHS-006 administered via IV Q3W.
Other Names:
Arm B participants will receive toripalimab administered via IV Q3W.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of the number of participants with treatment-emergent adverse events (TEAEs) receiving CHS-006 administered in combination with toripalimab
Time Frame: Day 1 of study treatment through up to 90 days post last dose of study treatment
|
Assessed by number of participants with TEAEs assessed by the investigator as per CTCAE v5.0.
|
Day 1 of study treatment through up to 90 days post last dose of study treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Description of the PK profile of CHS-006 in combination with toripalimab
Time Frame: Measured at multiple timepoints from Day 1 of study treatment through up to 90 days post last dose of study treatment
|
Assessed by serum concentration of CHS-006 and toripalimab as determined by validated assays
|
Measured at multiple timepoints from Day 1 of study treatment through up to 90 days post last dose of study treatment
|
Immunogenicity of CHS-006 and/or toripalimab
Time Frame: Measured at multiple timepoints from Day 1 of study treatment through up to 90 days post last dose of study treatment
|
Percentage of participants who develop treatment-emergent antidrug antibodies (ADA) to CHS-006 and/or toripalimab
|
Measured at multiple timepoints from Day 1 of study treatment through up to 90 days post last dose of study treatment
|
Objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 assessed by the investigator
Time Frame: Measured at multiple timepoints from Day 1 of study treatment through +/- 7 days at the completion of or premature withdrawal from the study
|
Investigator-assessed ORR as per RECIST v1.1
|
Measured at multiple timepoints from Day 1 of study treatment through +/- 7 days at the completion of or premature withdrawal from the study
|
Duration of response (DoR) using RECIST v1.1 assessed by the investigator
Time Frame: Measured at multiple timepoints from Day 1 of study treatment through +/- 7 days at the completion of or premature withdrawal from the study
|
Investigator-assessed DoR as per RECIST v1.1
|
Measured at multiple timepoints from Day 1 of study treatment through +/- 7 days at the completion of or premature withdrawal from the study
|
Disease control rate (DCR) using RECIST v1.1 assessed by the investigator
Time Frame: Measured at multiple timepoints from Day 1 of study treatment through +/- 7 days at the completion of or premature withdrawal from the study
|
Investigator-assessed DCR as per RECIST v1.1
|
Measured at multiple timepoints from Day 1 of study treatment through +/- 7 days at the completion of or premature withdrawal from the study
|
Time to response (TTR) using RECIST v1.1 assessed by the investigator
Time Frame: Measured at multiple timepoints from Day 1 of study treatment through +/- 7 days at the completion of or premature withdrawal from the study
|
Investigator-assessed TTR as per RECIST v1.1
|
Measured at multiple timepoints from Day 1 of study treatment through +/- 7 days at the completion of or premature withdrawal from the study
|
Progression-free survival (PFS) using RECIST v1.1 assessed by the investigator
Time Frame: Measured at multiple timepoints from Day 1 of study treatment through +/- 7 days at the completion of or premature withdrawal from the study
|
Investigator-assessed PFS as per RECIST v1.1
|
Measured at multiple timepoints from Day 1 of study treatment through +/- 7 days at the completion of or premature withdrawal from the study
|
Overall survival (OS) using RECIST v1.1 assessed by the investigator
Time Frame: Measured at multiple timepoints from Day 1 of study treatment through +/- 7 days at the completion of or premature withdrawal from the study
|
Investigator-assessed PFS as per RECIST v1.1
|
Measured at multiple timepoints from Day 1 of study treatment through +/- 7 days at the completion of or premature withdrawal from the study
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 26, 2023
Primary Completion (Estimated)
January 1, 2026
Study Completion (Estimated)
January 1, 2026
Study Registration Dates
First Submitted
January 2, 2023
First Submitted That Met QC Criteria
February 23, 2023
First Posted (Actual)
March 7, 2023
Study Record Updates
Last Update Posted (Actual)
February 20, 2024
Last Update Submitted That Met QC Criteria
February 16, 2024
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHS-006-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI); Genentech, Inc.RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditionsUnited States, Canada, Puerto Rico
-
Edward KimBristol-Myers Squibb; National Cancer Institute (NCI)TerminatedUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)CompletedStage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular CarcinomaUnited States
Clinical Trials on CHS-006 (anti-TIGIT)
-
Shanghai Huaota Biopharmaceutical Co., Ltd.RecruitingNSCLC | Advanced Solid TumorUnited States, China
-
Alain AlgaziGenentech, Inc.RecruitingCarcinoma | Cancer | Head and Neck Cancer | Squamous Cell CarcinomaUnited States
-
Coherus Biosciences, Inc.CompletedPlaque PsoriasisUnited States, Canada, Bulgaria, Chile, Croatia, Estonia, Georgia, Israel, Italy, Latvia, Moldova, Republic of, Poland, Russian Federation, Slovakia, South Africa, Ukraine
-
OncoMed Pharmaceuticals, Inc.TerminatedMetastatic Cancer | Locally Advanced CancerUnited States
-
Shanghai Henlius BiotechRecruitingLymphoma | Advanced Tumors | Metastatic TumorsChina
-
Bio-Thera SolutionsTerminatedAdvanced Solid TumorAustralia
-
OmicoHoffmann-La Roche; The George Institute for Global Health, AustraliaRecruitingSolid Tumor, AdultAustralia
-
Huabo Biopharm Co., Ltd.First Affiliated Hospital Bengbu Medical CollegeRecruiting
-
M.D. Anderson Cancer CenterActive, not recruitingRecurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Ovarian Clear Cell Adenocarcinoma | Recurrent Platinum-Resistant Fallopian Tube Carcinoma | Recurrent Platinum-Resistant Primary Peritoneal Carcinoma | Recurrent Primary Peritoneal...United States
-
Coherus Biosciences, Inc.Daiichi Sankyo Co., Ltd.CompletedRheumatoid ArthritisUnited States, Spain, Israel, Belarus, Japan, Poland, Hungary, South Africa, Germany, Russian Federation, France, United Kingdom